Pancreatic cancer is the fourth leading cause of cancer death in the United States ([@bib28]) and the fifth in Japan. It is often nonresectable at the time of diagnosis, and is generally associated with a poor prognosis. However, recent advances in chemotherapy have prolonged the survival time of patients with nonresectable pancreatic cancer ([@bib22]; [@bib4]; [@bib31]). Systemic administration of gemcitabine has been the mainstream first-line chemotherapy for nonresectable pancreatic cancer, since [@bib3] demonstrated the superiority of gemcitabine over 5-fluorouracil. More recently, gemcitabine-based combination chemotherapies have been intensely investigated ([@bib8]; [@bib24]; [@bib35]), but few trials have shown their superiority over gemcitabine monotherapy ([@bib19]; [@bib37]).

In this setting, reliable prognostic information is desired for tailored management of individual patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. The most widely used staging system for pancreatic cancer is the American Joint Committee on Cancer (AJCC) TNM staging system ([@bib5]). However, it is relatively nondiscriminatory for survival prediction in nonresectable pancreatic cancer, which is mostly diagnosed as TNM stage III or IV.

A nomogram is a simple graphical presentation of a multivariate predictive model showing the impact of each included variable on an outcome of interest that provides a numerical probability of the outcome ([@bib9]), and is progressively being used as a useful predictive tool for cancer prognosis in the field of oncology ([@bib15], [@bib14]; [@bib11]; [@bib34]). Several prognostic factors for survival of nonresectable pancreatic cancer have been reported ([@bib12]; [@bib36]; [@bib27]; [@bib25], [@bib23]), but were evaluated separately in different cohorts. One of the strengths of a nomogram is the ability to integrate multiple prognostic factors into a single numerical estimate of survival in an individual patient and thus provide an individualised prediction of survival. A nomogram to predict survival after resection of pancreatic cancer was generated by [@bib1] and has been validated externally as well as internally ([@bib6]). However, to our knowledge, a nomogram for survival prediction in nonresectable pancreatic cancer treated with chemotherapy has not been reported.

The aim of this study was to generate and internally validate a nomogram to predict survival in patients with nonresectable pancreatic cancer receiving gemcitabine-based chemotherapy.

Materials and methods
=====================

Patients
--------

From a collaborative prospective database of patients with pancreatic cancer including data from the University of Tokyo Hospital and affiliated hospitals, we identified consecutive patients who were diagnosed with nonresectable pancreatic cancer and subsequently received gemcitabine-based chemotherapy as the first-line anticancer treatment between June 2001 and February 2013. Pancreatic cancer was diagnosed by pathological examination or typical radiographic findings or by a clinical follow-up of at least 6 months. Nonresectability was confirmed via consultation with the departments of surgery and anaesthesiology in each hospital. Patients were followed-up at least every 2 weeks on an outpatient basis, and the tumour responses were evaluated by computed tomography, which was performed at baseline and then after every two cycles (8 weeks), according to the Response Evaluation Criteria in Solid Tumors, version 1.0 ([@bib32]). Follow-up was performed until October 2013. The study was approved by the ethics committee at each institution.

Gemcitabine-based chemotherapy
------------------------------

Patients received gemcitabine alone or in combination with S-1, candesartan, or erlotinib. The regimen of each chemotherapy was as follows. For gemcitabine monotherapy, gemcitabine was administered intravenously at 1000 mg m^−2^ on days 1,8, and 15 within each 4-week cycle. For gemcitabine and S-1, gemcitabine was administered intravenously at 1000 mg m^−2^ on days 1 and 15, and S-1 was given orally b.i.d. from days 1 to 14 within each 4-week cycle. The doses of S-1 were determined according to the body surface area (BSA) as follows: BSA⩽1.25 m^2^, 80 mg per day; 1.25 m^2^\<BSA⩽1.5 m^2^, 100 mg per day; and BSA⩾1.5 m^2^, 120 mg per day. For gemcitabine and candesartan, gemcitabine monotherapy plus oral candesartan at a dose of 4--32 mg per day was administered within each 4-week cycle. For gemcitabine and erlotinib, gemcitabine monotherapy plus oral erlotinib at a dose of 100 or 150 mg per day was administered. Some of the patients were enrolled in our clinical trials: GEMSAP ([@bib24]) and GECA1/2 ([@bib20], [@bib21]).

AJCC TNM staging system
-----------------------

In the current staging system utilising T, N, and M factors (AJCC Cancer Staging Manual, 7th Edition, 2010) ([@bib5]), the pancreatic cancer stages are categorized as follows: Stage IA, T1 N0 M0; Stage IB, T2 N0 M0; Stage IIA, T3 N0 M0; Stage IIB, T1--3 N1 M0; Stage III, T4 N-any M0; and Stage IV, T-any N-any M1.

Statistical analysis
--------------------

Survival time was defined as the time from initiation of chemotherapy to all-cause death. Patients who were alive at the last follow-up or lost to follow-up were treated as censored at the time of last follow-up. Survival times were estimated using the Kaplan--Meier method and compared using the log-rank test. The 95% confidence interval (CI) of the median survival time (MST) was calculated ([@bib2]) and that of the survival rate was also calculated by the formula of Greenwood ([@bib13]).

The multivariate Cox proportional hazards model was used to generate a nomogram to predict survival probabilities at 6, 12, and 18 months and MST. The following variables were included: age; sex; performance status based on the criteria of the Eastern Cooperative Oncology Group; tumour size; regional lymph node metastasis (AJCC N-factor); and distant metastasis (AJCC M-factor). Tumour size was defined as the maximum diameter of a primary tumour based on the findings of computed tomography. The performance status values of 2 and 3 were grouped because of the small numbers of patients. The proportional hazards assumption of each variable was verified by Schoenfeld residual plots.

The newly generated nomogram was internally validated via two steps. First, the nomogram was subjected to bootstrapping with 1000 resamples to calculate a relatively unbiased measure of its ability to discriminate the survival times of two patients(concordance index).The concordance index quantifies the level of concordance between predicted probabilities and actual outcomes, and ranges from 0.5 (no discrimination at all) to 1.0 (perfect discrimination). In other words, it reflects the probability that a patient with a lower probability of survival predicted via the nomogram dies earlier than another patient with a higher predicted probability, when considering two patients randomly selected from the study population. Second, the predicted probability was compared with the observed frequency in the total study population, again using bootstrapping with 1000 resamples to reduce an overfit bias (calibration).

The superiority of the present nomogram over the AJCC TNM staging system for survival prediction was confirmed as follows. The bias-corrected concordance indexes of the nomogram and the AJCC TNM staging system were calculated to compare their predictive abilities for survival. The heterogeneity of survival within each AJCC stage was evaluated by demonstrating histograms of nomogram-predicted survival probabilities. Stratification of actual survival via the nomogram-predicted probabilities was illustrated by categorising the total cohort according to quartiles of the probabilities and comparing survival times between the groups.

All analyses were performed using R software version 2.15.2 (R Development Core Team; <http://www.r-project.org>) and the *RMS* package developed by Harrell ([@bib7]). Values of *P*\<0.05 were considered statistically significant, and all tests were two sided.

Results
=======

Patient characteristics
-----------------------

In total, 531 consecutive patients who received gemcitabine-based chemotherapy as first-line chemotherapy for nonresectable pancreatic cancer were identified. The patient characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. The MST of the study population was 11.3 months (95% CI: 10.2--12.8 months), and the survival rates at 6, 12, and 18 months were 73.5% (95% CI: 69.8--77.5%), 47.2% (95% CI: 42.9--51.9%), and 28.9% (95% CI: 24.9--33.5%), respectively. At last follow-up, 442 patients (83.2%) had died, with a median follow-up time of 9.4 months.

Generation and internal validation of a prognostic nomogram
-----------------------------------------------------------

A nomogram was generated via the Cox proportional hazards model including the above mentioned variables, and is demonstrated with brief instructions for its usage in [Figure 1](#fig1){ref-type="fig"}. The results of the underlying univariate and multivariate Cox models for survival time are shown in [Table 2](#tbl2){ref-type="table"}. The nomogram predicts the survival probabilities of 6, 12, and 18 months and the MST after initiation of chemotherapy in a given patient. For example, a 65-year-old ('Points\'=10) male ('Points\'=5) patient with performance status of 1 ('Points\'=20), tumour size of 60 mm ('Points\'=33), regional lymph node metastasis ('Points\'=15), and absence of distant metastasis ('Points\'=0) has a 'Total Points\' score of 69, which corresponds to 6-, 12-, and 18-month-predicted survival probabilities of 80%, 54%, and 34%, respectively, and to predicted MST of 13 months.

The bias-corrected concordance indexes of the present nomogram were higher than those of the AJCC TNM staging system at all time points (0.686 *vs* 0.612 for 6-month survival; 0.686 *vs* 0.612 for 12-month survival; and 0.686 *vs* 0.611 for 18-month survival).These results demonstrated that the discrimination via the newly generated nomogram was superior to the grouping via the AJCC TNM staging system. Calibration plots of the 6-, 12-, and 18-month survival are shown in [Figure 2](#fig2){ref-type="fig"}. The mean absolute errors between the observed and predicted probabilities were 0.019, 0.045, and 0.038 for 6-, 12-, and 18-month survival, respectively, and the errors for 90% of the study population were within 0.046, 0.027, and 0.057, respectively.

AJCC TNM staging and nomogram-predicted survival probabilities
--------------------------------------------------------------

[Figure 3](#fig3){ref-type="fig"} illustrates histograms of nomogram-predicted survival probabilities at 12 months after initiation of chemotherapy within each of the TNM stages (III and IV). There was considerable heterogeneity in the nomogram-predicted survival probabilities even for the same TNM stage.

Survival time according to risk stratification based on nomogram-predicted survival probabilities
-------------------------------------------------------------------------------------------------

On the basis of nomogram-predicted survival probabilities, the patients were categorised into the following quartiles of risk: very low ('Total Points\': ⩽54); low (55--81); high (82--105); and very high (⩾106). [Figure 4](#fig4){ref-type="fig"} illustrates the Kaplan--Meier survival curves according to the nomogram-based groupings. The survival times were significantly differentiated between the groups (*P*\<0.001). The MSTs in the very low-, low-, high-, and very high-risk groups were 17.5 (95% CI: 15.4--22.9), 13.7 (95% CI: 11.6--16.0), 8.9 (95% CI: 7.9--10.4), and 5.5 (95% CI: 4.7--7.5) months, respectively.

Discussion
==========

The present prognostic nomogram derived from prospectively collected data on 531 patients from five hospitals was shown to provide improved ability for individualised survival prediction in patients with nonresectable pancreatic cancer receiving gemcitabine-based chemotherapy, compared with the existing TNM staging system. By using this nomogram, individualisation of patient counselling and decision-making regarding management can be promoted.

Patients with nonresectable pancreatic cancer have a very high probability of ultimately dying of their primary disease. However, given the improved survival via recent advances in chemotherapy for this condition ([@bib22]; [@bib4]; [@bib31]), the importance of tailored management of patients with nonresectable pancreatic cancer has increased, and clinical physicians and patients alike desire reliable prognostic information tailored to individual patients. Although the AJCC has developed and revised a TNM staging system for pancreatic neoplasms ([@bib5]), it was not specifically developed for survival prediction of nonresectable cases, but instead was rather related to resectability evaluation and preoperative staging. In this staging system, most patients with nonresectable pancreatic cancer are diagnosed as stage III or IV, and are thus only dichotomised. Therefore, the TNM staging system is relatively nondiscriminatory as a means for survival prediction of nonresectable pancreatic cancer treated with chemotherapy. Actually, within the group at each TNM stage in the present study, considerable heterogeneity was found in terms of nomogram-predicted survival probabilities among the patients ([Figure 3](#fig3){ref-type="fig"}). In other words, the patients were associated with various survival times, even if they were diagnosed as the same TNM stage.

A nomogram was developed as a statistical tool to provide the overall probability of a specific outcome via a simple graphical presentation, and was shown to be more accurate than conventional staging systems for predicting prognosis in various malignancies ([@bib15], [@bib14]; [@bib11]) and benign diseases ([@bib16]; [@bib29], [@bib30]). As a nomogram is simple and understandable, it has been easily introduced into daily clinical practice. In addition, a nomogram can generate individualised predictions, and thus patients can be evaluated for their participation in clinical trials using this tool. For example, several randomised controlled trials have included expected survival time in their eligibility criteria, and a nomogram that can more accurately predict survival can provide valuable information for this consideration, potentially making such trials more sophisticated ([@bib9]).

In this study, we aimed to generate and internally validate a nomogram to overcome the above mentioned drawbacks of the TNM staging system as a means for survival prediction in patients with nonresectable pancreatic cancer receiving chemotherapy. The present nomogram included the following six variables that can be readily determined, thus providing information on predicted survival at the time of chemotherapy initiation: age; sex; performance status; tumour size; regional lymph node metastasis; and distant metastasis. Age and sex are baseline characteristics of patients. Performance status, which was reported to be a significant risk factor for survival in nonresectable pancreatic cancer ([@bib12]; [@bib36]; [@bib27]), can be determined by physical examinations, and the remaining factors by computed tomography, which is routinely performed for patients with unresectable pancreatic cancer. In addition, no specific molecular markers ([@bib18]; [@bib17]) are required for this nomogram. Therefore, survival prediction via the present nomogram can be made immediately at an outpatient clinic without any additional costs, potentially providing valuable information for decision-making regarding treatments early after diagnosis of the disease. Carbohydrate antigen 19-9 (CA 19-9) is widely recognised as a prognostic factor for pancreatic cancer ([@bib36]; [@bib10]; [@bib25]). However, patients whose red blood cell phenotyping for both Lewis A and B antigens is negative are unable to secrete CA 19-9 into their serum. Therefore, we did not include this variable in the model to secure usability for the general population, but did include tumour size, which is positively correlated with CA 19-9 ([@bib26]; [@bib33]).

Overall, the internal validation demonstrated good fitness for survival prediction at several specific time points, as the predicted survival probabilities at 6, 12, and 18 months estimated via the nomogram were closely aligned with the actual survival times. Again, [Figure 3](#fig3){ref-type="fig"} emphasizes that our nomogram provides a more differentiating prediction model compared with the AJCC TNM staging system. [Figure 4](#fig4){ref-type="fig"} shows a clear risk stratification of survival times using nomogram-predicted survival probabilities. Therefore, using this nomogram, physicians can predict their patients\' prognosis, provide more informative explanations to the patients, and initiate more individualised management.

There are limitations to be addressed in the present study. First, all potential predictive variables could never be included in the analysis to generate a nomogram with an absolute predictive ability. However, the internal validation demonstrated good fitness of the present nomogram based on the six variables for survival prediction. Nonetheless, we should recognise that bootstrapping is a sample reuse method that is useful to mitigate an overfit bias of the data for nomogram generation, but cannot ensure applicability to an external cohort. Therefore, our nomogram should be externally validated using an independent population in the future. Second, despite our use of a large multicenter collaborative database that provides prospectively collected data on patients with nonresectable pancreatic cancer, some of the patients were not followed-up until death.

In conclusion, the present nomogram can predict the prognosis of patients with unresectable pancreatic cancer receiving gemcitabine-based chemotherapy with considerable accuracy, potentially facilitating highly tailored patient management.
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![**A nomogram to predict the survival of patients with nonresectable pancreatic cancer receiving gemcitabine-based chemotherapy.** To estimate survival in a given patient, the 'Total Points\' score is calculated by summing the respective 'Points\'values corresponding to each variable. Using this 'Total Points\' score, the survival probabilities at 6, 12, and 18 months and the median survival time can be predicted according to the lower scales.](bjc2014131f1){#fig1}

![**Calibration plots of the present nomogram for 6-, 12-, and 18-month survival that were adjusted by bootstrapping with 1000 resamples ((A) 6 months; (B) 12 months; and (C) 18 months).** The diagonal line indicates the ideal nomogram reference.](bjc2014131f2){#fig2}

![**Histograms of nomogram-predicted survival probabilities at 12 months after initiation of chemotherapy within each AJCC TNM stage.** Abbreviation: AJCC, American Joint Committee on Cancer.](bjc2014131f3){#fig3}

![**Kaplan--Meier survival curves according to the quartiles of nomogram-predicted survival probabilities.** The survival times were significantly differentiated between the groups (*P*\<0.001).](bjc2014131f4){#fig4}

###### Characteristics of the 531 patients with nonresectable pancreatic cancer who received gemcitabine-based chemotherapy

  ------------------------------------------------- -------------------------------------
  **Age, years**                                    
  Median (range)                                                 68 (35--89)
  **Sex,** ***n*** **(%)**                          
  Male/female                                                306/225 (57.6/42.4)
  **ECOG performance status,** ***n*** **(%)**      
  0/1/2/3                                             190/276/63/2 (35.8/51.9/11.9/0.4)
  **Location of primary tumour,** ***n*** **(%)**   
  Head/body/tail of the pancreas                        267/157/107 (50.2/29.6/20.2)
  **Tumour size, (mm)**                             
  Median (range)                                                35 (14--170)
  Distant metastasis, *n* (%)                                    327 (61.6)
  **Site of metastasis,** ***n*** **(%)**           
  Liver/lung/lymph node/peritoneum                   220/60/271/84 (41.4/11.3/51.0/15.8)
  **CEA, IU/l**                                     
  Median (range)                                               5.2 (0.7--3948)
  **CA19-9, IU/l**                                  
  Median (range)                                              493 (1--57 4000)
  **AJCC stage,** ***n*** **(%)**                   
  III/IV                                                     204/327 (38.4/61.6)
  **Chemotherapy,** ***n*** **(%)**                 
  Gemcitabine monotherapy                                        374 (70.5)
  Gemcitabine and S-1                                            108 (20.3)
  Gemcitabine and candesartan                                     41 (7.7)
  Gemcitabine and erlotinib                                        8 (1.5)
  ------------------------------------------------- -------------------------------------

Abbreviations: AJCC=American Joint Committee on Cancer; CA 19-9=carbohydrate antigen 19-9; CEA=carcinoembryonic antigen; ECOG=Eastern Cooperative Oncology Group.

###### Univariate and multivariate Cox proportional hazards models to predict survival in patients with nonresectable pancreatic cancer receiving gemcitabine-based chemotherapy

                                       **Univariate analysis**    **Multivariate analysis**                                       
  ------------------------------------ ------------------------- --------------------------- --------- ----------- -------------- ---------
  Age                                  0.989                            0.979--0.998         0.024     0.993        0.983--1.004  0.202
  **Sex**                                                                                                                         
  Female                               Reference                                                       Reference                   
  Male                                 1.074                            0.885--1.306         0.473     1.086        0.892--1.323  0.413
  **Performance status**                                                                                                          
  0                                    Reference                                                       Reference                   
  1                                    1.413                            1.148--1.742         0.001     1.393        1.131--1.720  0.002
  2--3                                 4.359                            3.079--6.067         \<0.001   4.706        3.292--6.622  \<0.001
  Tumour size                          1.015                            1.010--1.021         \<0.001   1.009        1.004--1.014  0.001
  **Regional lymph node metastasis**                                                                                              
  No                                   Reference                                                       Reference                   
  Yes                                  1.551                            1.279--1.882         \<0.001   1.276        1.043--1.562  0.018
  **Distant metastasis**                                                                                                          
  No                                   Reference                                                       Reference                   
  Yes                                  2.098                            1.713--2.580         \<0.001   1.866        1.514--2.308  \<0.001

Abbreviations: CI=confidence interval; HR=hazards ratio.

Tumour size was defined as the maximum diameter of a primary tumour. Performance status was determined according to the criteria of the Eastern Cooperative Oncology Group.
